MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma

BackgroundAccumulating evidence confirm that aberrant microRNAs (miRNAs) expression contributes to hepatocellular carcinoma (HCC) development and progression. Previous study reported that miR-1468 showed an up-regulated tendency and might be a potential prognostic biomarker in HCC samples derived from TCGA database. However, the role of miR-1468 and its underlying mechanisms involved in the growth and metastasis of HCC remain poorly investigated.MethodsCCK-8, EdU, colony formation and flow cytometry were used to determine proliferation, cell cycle progression and apoptosis of HCC cells in vitro. The subcutaneous tumor model in nude mice was established to detect tumor growth of HCC in vivo. The direct binding of miR-1468 to 3’UTR of Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 (CITED2) and Up-frameshift protein 1 (UPF1) was confirmed by luciferase reporter assay.ResultsHere, we demonstrated that miR-1468 expression was up-regulated in HCC tissues and cell lines. Clinical analysis revealed that increased miR-1468 level was significantly correlated with malignant prognostic features and shorter survival. Gain- and loss-of-function experiments indicated that miR-1468 promoted cell proliferation, colony formation, cell cycle progression and induced apoptosis of HCC cells in vitro and in vivo. Moreover, CITED2 and UPF1 were identified as direct downstream targets of miR-1468 in HCC cells, and mediated the functional effects of miR-1468 in HCC, resulting in peroxisome proliferator-activated receptor-γ (PPAR-γ)/AKT signaling activation. In clinical samples of HCC, miR-1468 inversely correlated with the levels of CITED2 and UPF1, which were confirmed to be down-regulated in HCC. Restoration of CITED2 or UPF1 expression at least partially abolished the biological effects of miR-1468 on HCC cells. Moreover, alteration of PPAR-γ or AKT phosphorylation could reverse the function of miR-1468 in HCC.ConclusionsTaken together, this research supports the first evidence that miR-1468 plays an oncogenic role in HCC via activating PPAR-γ/AKT pathway by targeting CITED2 and UPF1, and represents a promising therapeutic strategy for HCC patients.

[1]  Xin Zheng,et al.  High‑mobility group box 1 has a prognostic role and contributes to epithelial mesenchymal transition in human hepatocellular carcinoma. , 2015, Molecular medicine reports.

[2]  Meng Xu,et al.  Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma , 2016, Oncotarget.

[3]  Wei Yang,et al.  MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma , 2015, International journal of oncology.

[4]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[5]  Yu-qin Pan,et al.  MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma , 2016, OncoTargets and therapy.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  A. Covey,et al.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.

[8]  Krishna R. Kalari,et al.  Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study , 2012, BMC Cancer.

[9]  H. Koeffler Peroxisome proliferator-activated receptor γ and cancers , 2003 .

[10]  Zhongliang Zhu,et al.  The human RNA surveillance factor Up-frameshift 1 inhibits hepatic cancer progression by targeting MRP2/ABCC2. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  David S. Park,et al.  CITED2 Signals through Peroxisome Proliferator-Activated Receptor-γ to Regulate Death of Cortical Neurons after DNA Damage , 2008, The Journal of Neuroscience.

[12]  E. Lam,et al.  Cited2, a coactivator of HNF4α, is essential for liver development , 2007 .

[13]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[14]  Ming Shi,et al.  Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[15]  Helen C. Hurst,et al.  Physical and Functional Interactions among AP-2 Transcription Factors, p300/CREB-binding Protein, and CITED2* , 2003, The Journal of Biological Chemistry.

[16]  E. Lam,et al.  Cited2, a coactivator of HNF4alpha, is essential for liver development. , 2007, EMBO Journal.

[17]  Jie Sun,et al.  MicroRNAs in Hepatocellular Carcinoma: Regulation, Function, and Clinical Implications , 2013, TheScientificWorldJournal.

[18]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[19]  C. Weng,et al.  Excavatolide B inhibits nonsmall cell lung cancer proliferation by altering peroxisome proliferator activated receptor gamma expression and PTEN/AKT/NF‐Kβ expression , 2017, Environmental toxicology.

[20]  J. W. Davis,et al.  Identification of the CREB-binding Protein/p300-interacting Protein CITED2 as a Peroxisome Proliferator-activated Receptor α Coregulator* , 2004, Journal of Biological Chemistry.

[21]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[22]  Xin Zheng,et al.  RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. , 2015, International journal of oncology.

[23]  Jun Yu,et al.  CITED2 is a Novel Direct Effector of Peroxisome Proliferator-Activated Receptor Gamma in Suppressing Hepatocellular Carcinoma Cell Growth , 2011 .

[24]  Quanyan Liu,et al.  The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma , 2016, Journal of Experimental & Clinical Cancer Research.

[25]  G. A. Ganepola,et al.  Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. , 2014, World journal of gastrointestinal oncology.

[26]  Jun Yu,et al.  Functional role of peroxisome‐proliferator‐activated receptor γ in hepatocellular carcinoma , 2012, Journal of gastroenterology and hepatology.

[27]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[28]  Meng Xu,et al.  Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma , 2016, Oncotarget.

[29]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[30]  P. Malfertheiner,et al.  Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo , 2006, Hepatology.

[31]  Jun Yu,et al.  CITED2 is a novel direct effector of peroxisome proliferator‐activated receptor γ in suppressing hepatocellular carcinoma cell growth , 2013, Cancer.

[32]  Yingyi Wang,et al.  MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1. , 2017, American journal of cancer research.

[33]  H. Koeffler Peroxisome proliferator-activated receptor gamma and cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Gang Liu,et al.  A five‐miRNA expression signature predicts survival in hepatocellular carcinoma , 2017, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[35]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[36]  Wei Yang,et al.  MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1 , 2015, Oncotarget.

[37]  Xin Zheng,et al.  MicroRNA-130b Promotes Cell Aggressiveness by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Human Hepatocellular Carcinoma , 2014, International journal of molecular sciences.

[38]  D. Yoon,et al.  Peroxisome proliferator-activated receptor-gamma agonist 4-O-methylhonokiol induces apoptosis by triggering the intrinsic apoptosis pathway and inhibiting the PI3K/Akt survival pathway in SiHa human cervical cancer cells. , 2015, Journal of Microbiology and Biotechnology.

[39]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.

[40]  Miao Sun,et al.  MicroRNA and cancer: Current status and prospective , 2006, International journal of cancer.

[41]  Takashi Suzuki,et al.  CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance , 2016, Cancer science.

[42]  Jun Yu,et al.  Inhibitory role of peroxisome proliferator‐activated receptor gamma in hepatocarcinogenesis in mice and in vitro , 2010, Hepatology.

[43]  C. Azzalin,et al.  The Human RNA Surveillance Factor UPF1 Is Required for S Phase Progression and Genome Stability , 2006, Current Biology.

[44]  You-cai Zhao,et al.  Expression Profiles and Clinical Significance of MicroRNAs in Papillary Renal Cell Carcinoma , 2015, Medicine.

[45]  J. Tu,et al.  MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway , 2017, Molecular Cancer.

[46]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[47]  Zhikui Liu,et al.  MiR-4319 induced an inhibition of epithelial-mesenchymal transition and prevented cancer stemness of HCC through targeting FOXQ1 , 2019, International journal of biological sciences.

[48]  Stephanie Roessler,et al.  MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.